Research activities of the Department of Dermatology, Zurich University Hospital
Our research activities are primarily focussed on basic, patient-oriented translational, and clinical research in:
- Dermato-oncology, where we focus on the pathogenesis, early diagnosis and molecular targeted treatment of skin cancer, particularly in melanoma, cutaneous lymphoma, and non-melanoma skin cancers.
- Immunodermatology, especially innate immunity and T-cell biology in inflammatory skin diseases, notably psoriasis, neutrophilic dermatoses, cutaneous drug eruptions, and severe allergic adverse drug reactions.
- Allergology, emphasizing on drug and food allergies, and specific immunotherapy.
The Departments Research Groups
Clinical Trials
Highlights
Approx. 50 ongoing clinical trials on new therapeutic approaches in skin disease.
FPFV= First patient first visit
LPLV= Last patient last visit
NOP= Number of patient
Protocol | Study title | FPFV | LPLV | NoP | PI |
---|---|---|---|---|---|
Abbott Humira | Nicht vorhanden | 18/02/2008 | 07/08/2008 | 2 | Prof. R. Trüeb |
Abbott M10-016 | "A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With ABT-874" | 13/07/2009 | 11/05/2011 | 6 | Prof. L. French |
Abbott ABT-874-255 | Nicht vorhanden | 07/07/2008 | 29/12/2008 | 8 | Prof. R. Trüeb |
Abbott ABT-874-255-2 | Nicht vorhanden | 10/10/2008 | 02/06/2009 | 7 | Prof. R. Trüeb |
AbbottABT-874-255-3 | Nicht vorhanden | 27/03/2009 | 19/10/2009 | 6 | Prof. R. Trüeb |
Abbvie H13-147 | "An Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult and Adolescent Patients with Hidradenitis Suppurativa – UNITE" | 02/02/2015 | ongoing | 3 | Prof. L. French |
Actelion AC-085A201 | "A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of two doses of ACT-128800, an oral S1P1 receptor agonist, administered up to twenty-eight weeks in patients with moderate to severe chronic plaque psoriasis" | 02/05/2011 | 29/03/2012 | 4 | Prof. L. French |
ALIGN | "ALIGN – Multi-country, cross sectionAL study to determine patient specIfic and General beliefs towards medicatioN and their treatment compliance to selected systemic therapies in chronic inflammatory diseases (IMID)" | 19/02/2013 | 20/02/2013 | 10 | Prof. L. French |
Amgen 20120102 | "A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1" | 15/10/2012 | 25/08/2015 | 4 | Prof. L. French |
CAIN457A2304E1 | "A multicenter, double-blind and open label, 4 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen" | 11/03/2013 | ongoing | 3 | Prof. L. French |
CAIN457A3302_OPTIMISE | "Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg s.c." | 07/01/2016 | ongoing | 4 | Prof. L. French |
Celgene PSOR009 | "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS" | 22/11/2011 | 06/11/2012 | 1 | Prof. L. French |
Centocor-Studie C0743T09 | "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis" | 31/06/2006 | 21/02/2011 | 1 | Prof. L. French |
Creabilis CT 327 PV 01-09 | "A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a topical cream formulation of Pegylated K252a, when administered twice daily for Eight Weeks to Patients with Mild to Moderate Psoriasis Vulgaris." | 07/07/2010 | 29/12/2010 | 5 | Prof. L. French |
Eli Lilly RHBS | "Protocol I1F-MC-RHBS(a) A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis" | 10/11/2015 | ongoing | 6 | Prof. L. French |
Haemopep | Nicht vorhanden | 17/03/2008 | 09/11/2009 | 25 | Prof. R. Trüeb |
Hidradenitis M11-810 | "A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa" | 18/02/2013 | 21/11/2013 | 6 | Prof. L. French |
Hidradenitis M12-555 | "A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa" | 06/11/2013 | 02/06/2016 | 5 | Prof. L. French |
IBSA | Nicht vorhanden | 24/05/2006 | 25/09/2007 | 19 | Prof. R. Trüeb |
IMTM-Studie | Nicht vorhanden | 05/02/2009 | 30/06/2011 | 19 | Prof. L. French |
Novartis CAIN457A2304 | "A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens vs reTreatment Upon start of RElapse (SCULPTURE)" | 14/02/2012 | 18/02/2013 | 2 | Prof. L. French |
Novartis HS CJM112X2202 | "A randomized, double-blind, placebo controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate to severe chronic hidradenitis suppurativa patients" | 10/07/2015 | ongoing | 5 | Prof. L. French |
Pantogar 60+ | Nicht vorhanden | 03/03/2008 | 25/02/2010 | 85 | Prof. R. Trüeb |
Pyoderma | "A PHASE II MULTI CENTER OPEN LABEL PILOT STUDY TO ASSESS A POTENTIAL EFFECT OF AN ANTI-IL-1-? ANTAGONIST IN THE TREATMENT OF PYODERMA GANGRENOSUM" | 28/04/2011 | 21/10/2014 | 6 | Prof. L. French |
Remicade (Essex) | Nicht vorhanden | 23/03/2007 | 14/09/2007 | 7 | Prof. R. Trüeb |
SDNTT | "Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg." | 29/11/2011 | ongoing | 195 | Prof. L. French |
Urticana | "A PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED SINGLE CENTER STUDY OF CANAKINUMAB TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE CHRONIC IDIOPATHIC URTICARIA" | 15/08/2012 | 02/12/2013 | 13 | Prof. L. French |
Wolff | Nicht vorhanden | 10/04/2006 | 07/12/2007 | 28 | Prof. R. Trüeb |
Wyeth | Nicht vorhanden | 27/01/2006 | 18/01/2007 | 5 | Prof. R. Trüeb |